Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Diabetes meds in TGA recall

Posted 19 November 2020

Results of the TGA's investigation into the potential contamination of Australian metformin medicines has led to the recall of a single batch of Apotex's product found to contain "higher levels" of carcinogenic NDMA.

Back in December 2019, the TGA began laboratory tests of a selection of immediate- and extended-release metformin medicines for the presence of cancer-causing agent NDMA after regulators overseas recalled some brands of the drug due to contamination.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios